MAP2K7 and cancer: Given that MEK inhibitor trametinib abrogated the MLN4924-induced PD-L1 upregulation (Fig. 2E), we next determined whether MEK inhibitor would also re-sensitize MLN4924-pretreated cancer cells to Jurkat cell killing.